about
Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseasesIdentification of a cytokine-induced antiapoptotic molecule anamorsin essential for definitive hematopoiesisRGS18 is a myeloerythroid lineage-specific regulator of G-protein-signalling molecule highly expressed in megakaryocytesMegakaryocyte biology and related disordersEndothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in miceEndoreplication: polyploidy with purposeIdentification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopeniaTPO/Mpl Studies in Agnogenic Myeloid MetaplasiaThe pathophysiology of thrombocytopenia in chronic liver diseaseLinkage between the mechanisms of thrombocytopenia and thrombopoiesisPlatelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytesMutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopeniaLNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitorsZinc finger protein, Hzf, is required for megakaryocyte development and hemostasisLnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2Differential expression of NADPH oxidases in megakaryocytes and their role in polyploidyPoint mutation in the gene encoding p300 suppresses thrombocytopenia in Mpl-/- miceMERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin receptor signalingHematopoietic stem cell: self-renewal versus differentiationIncomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis.Analysis of thrombocyte development in CD41-GFP transgenic zebrafish.The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5.Complementary signaling through flt3 and interleukin-7 receptor alpha is indispensable for fetal and adult B cell genesisPolycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activityThrombopoietin.Hepatocyte growth factor/scatter factor enhances the thrombopoietin mRNA expression in rat hepatocytes and cirrhotic rat livers.Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions.Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytesHaematopoietic stem and progenitor cell-targeted therapies for thrombocytopenia.New insights and therapeutics for immune-mediated thrombocytopenia.An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominanceCongenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.MegakaryopoiesisCurrent status of thrombopoietic agents.Congenital amegakaryocytic thrombocytopenia: a brief review of the literatureThe development of romiplostim for patients with immune thrombocytopenia.Thrombopoietin and hematopoietic stem cells.Inherited platelet disorders: a clinical approach to diagnosis and management.
P2860
Q21296645-E497C9ED-EF8C-45F5-BA4C-608232696898Q24309295-45132DD4-65E6-4209-AD43-F399E0573F70Q24533459-69D71AFA-CAEF-4E1F-BD3A-4F16F46DA90FQ24536140-2196ED9C-9CFB-4B8C-83BA-B13552DFF196Q24652041-42067A9A-27F4-425C-A9DC-AAC457BD1B6CQ24654063-F6D33FC5-4E3F-4A16-94FF-400C6CC96955Q24672498-F807CB35-7AF0-498E-8C85-C6CE163A02A0Q24805242-9EAB6B11-4472-4E76-8C55-891ACB55863AQ26749277-268AD7FC-F2D3-4FBA-B3E2-AFB22E4396DDQ26770863-D5E4AF3F-EFC9-4F22-BF1C-647F240B8DF0Q27333563-1351A382-7FCB-469B-9588-1A131D600495Q28142403-AAB554EF-A7ED-4B26-AFBE-D747FF592CDFQ28145261-7500B446-C9F8-4952-83F7-0B32D65A099BQ28274115-675044C3-4402-4280-8514-75015E9C3717Q28504828-2EC71A80-6548-4560-881D-9677ED16E3DDQ28508573-321817EE-1BCD-4537-814C-2FA9D149ECD6Q28585549-778B93AF-9B92-4FE7-A9C0-0AF4ED477307Q28593767-50B5FA54-1135-4821-B1BA-BC6D042F391AQ28854388-F58C1F46-517C-42BB-8A2A-B297254174A4Q29396498-EF288435-D3AE-47BC-97BF-D9EE68CA217CQ30486155-C428DBBF-F621-4DA2-94C4-05C876846EFAQ30796563-A6FD820C-2342-4CC1-A962-0B5ED3130E3EQ31893762-7EC141FE-3674-4DE2-B10C-4FB9C1676A72Q33194891-B07B5E3B-8FA8-4BA7-8980-81A6DD503F48Q33328634-ADB6708A-3323-4585-8AFD-57752D0AE894Q33330090-9425BD00-016C-4FCA-A23D-4E971753AA84Q33331790-47A94CFA-D01D-4B69-9C4F-0BE8989F83C4Q33344528-9E5362B3-D562-44A7-BAF4-E8CD97E2D657Q33371036-A3BB9117-580D-4F55-9FB8-9CC2F731A3EFQ33372720-3CB0D64E-C6AD-4673-88D7-C9C26F3FD740Q33377901-CAF4F66D-1634-4941-9BE6-CF4E3132B5E2Q33382312-BD4B47ED-D8D5-4344-9955-0B169410EE7CQ33383921-9BB01273-6481-4803-91AA-7F898B245399Q33387735-8CA8439F-3361-40D7-B3E0-024BC257D6A3Q33390616-07A9989D-F507-4989-8CE7-F2E32851DD6EQ33392858-9214B701-0F7B-40CE-A4DE-39AA241A55EBQ33393255-8F71CFEC-7F2E-404B-B90E-5C2BA69DED6CQ33394636-E545D8E1-6AF3-4931-A795-0D97EF260586Q33394846-07149207-12B6-42F2-8EAE-4536C864AF18Q33396427-E9B69541-2E0C-4222-A822-B85102017E69
P2860
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Thrombocytopenia in c-mpl-deficient mice.
@ast
Thrombocytopenia in c-mpl-deficient mice.
@en
type
label
Thrombocytopenia in c-mpl-deficient mice.
@ast
Thrombocytopenia in c-mpl-deficient mice.
@en
prefLabel
Thrombocytopenia in c-mpl-deficient mice.
@ast
Thrombocytopenia in c-mpl-deficient mice.
@en
P2093
P356
P1433
P1476
Thrombocytopenia in c-mpl-deficient mice.
@en
P2093
Carver-Moore K
de Sauvage FJ
P304
P356
10.1126/SCIENCE.8073287
P407
P577
1994-09-01T00:00:00Z